Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5718131 | 0.84 | PDE10A (0.49) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL7067437 | 0.84 | CYP2A6 (0.65) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL1539107 | 0.83 | HPGDS (0.48) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL4865471 | 0.81 | PDE10A (0.49) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL4865849 | 0.79 | CYP2E1 (0.49) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL7990801 | 0.78 | CYP2E1 (0.53) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL12985709 | 0.78 | PDE10A (0.49) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL12985345 | 0.78 | PDE10A (0.49) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL8657334 | 0.77 | PDE10A (0.46) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL8921117 | 0.77 | HPGDS (0.51) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5847006-A | Therapeutic guanidines | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-12-08 | — | — | US | claimed |
| EP-0746316-A4 | THERAPEUTIC GUANIDINES | CAMBRIDGE NEUROSCIENCE INC (US) | 1997-12-10 | — | — | EP | claimed |
| EP-0746316-A1 | THERAPEUTIC GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1996-12-11 | — | — | EP | claimed |
| WO-1995014467-A1 | THERAPEUTIC GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-06-01 | — | — | WO | claimed |
| US-6673557-B2 | ADMINISTERING SUBSTITUED GUANIDINE COMPOUNDS FOR THERAPY OF DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2004-01-06 | — | — | US | disclosed |
| US-6673774-B2 | CLARITHROMYCIN MACROLIDES HAVING ENHANCED ACTIVITY TOWARDS GRAM-NEGATIVE BACTERIA AND MACROLIDE RESISTANT GRAM-POSITIVE BACTERIA; ACTIVE AGAINST MLSB-RESISTANT STRAINS (MLSB=MACROLIDES-LINCOSAMIDES-TYPE B STREPTOGRAMINES) | ENANTA PHARMACEUTICALS, INC. | 2004-01-06 | — | — | US | disclosed |
| US-6670331-B2 | Clarithromycin macrolides having enhanced activity towards gram-negative bacteria and macrolide resistant gram-positive bacteria; active against MLSB-resistant strains (MLSB=Macrolides-Lincosamides-type B Streptogramines) | ENANTA PHARMACEUTICALS, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030114396-A1 | 11-O-substituted macrolides and their descladinose derivatives | ENANTA PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030114395-A1 | Novel 11-O-substituted ketolide derivatives | ENANTA PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2003047600-A1 | 11-O-SUBSTITUTED MACROLIDES AND THEIR DESCLADINOSE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003047601-A1 | NOVEL 11-O-SUBSTITUTED KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6242198-B1 | ADMINISTERING GUANIDINE COMPOUND | CAMBRIDGE NEUROSCIENCE, INC. | 2001-06-05 | — | — | US | disclosed |
| EP-0918460-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5847006-A | Therapeutic guanidines | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1998004131-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0746316-A4 | THERAPEUTIC GUANIDINES | CAMBRIDGE NEUROSCIENCE INC (US) | 1997-12-10 | — | — | EP | disclosed |
| EP-0746316-A1 | THERAPEUTIC GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995014467-A1 | THERAPEUTIC GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | RBP4, ALDH1A2, RBP1 | PDE10A 1978/4885HPGDS 882/4885CYP2E1 4276/4885 |
| US-20030114396-A1 | 11-O-substituted macrolides and their descladinose derivatives | PIGS, TLR6, DDOST | PDE10A 721/4885HPGDS 1729/4885CYP2E1 882/4885 |
| US-20030114395-A1 | Novel 11-O-substituted ketolide derivatives | CYP51A1, CYP2C9, CYP4A11 | PDE10A 1831/4885HPGDS 662/4885CYP2E1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.